股票代码：688621 股票简称：阳光诺和 上市地点：上海证券交易所 （修订稿） | 项目 | 交易对方 | | --- | --- | | | 利虔、赣州朗颐投资中心（有限合伙）、刘宇晶、赣州国智股权投资合伙 | | | 企业（有限合伙）、杭州宏腾医药创业投资合伙企业（有限合伙）、杭州 | | | 方汭创业投资合伙企业（有限合伙）、杭州凯泰民德投资合伙企业（有限 | | | 合伙）、丽水同达创业投资合伙企业（有限合伙）、广州广发信德一期健 | | | 康产业投资企业（有限合伙）、杭州海达明德创业投资合伙企业（有限合 | | | 伙）、宁波海达睿盈创业投资合伙企业（有限合伙）、陈春能、广州易简 | | 发行股份 | 鼎虹股权投资合伙企业（有限合伙）、万海涛、苏州中誉赢嘉健康投资合 | | 及可转换 | 伙企业（有限合伙）、广州正达创业投资合伙企业（有限合伙）、康彦 | | | 龙、冯海霞、武汉火炬创业投资有限公司、武汉开发投资有限公司、珠海 | | 公司债券 | 横琴中润康健投资合伙企业（有限合伙）、嘉兴迦得股权投资合伙企业 | | 购买资产 | | | | （有限合伙）、广发乾和投资有限公司、杭州凯泰睿德创 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京阳光诺和药物研究股份有限公司（以下简称"公司"）近日收到上海证 券交易所科创板公司管理部下发的《关于北京阳光诺和药物研究股份有限公司重 组草案信息披露的问询函》（上证科创公函【2025】0394 号，以下简称"问询 函"）。 根据问询函的相关要求，公司会同本次交易相关方及中介机构对问询函所列 问题认真进行了逐项讨论核实，现就问询函相关内容作如下回复说明，并根据问 询函对有关问题进行了进一步说明和补充披露。本回复中涉及补充披露的内容已 以楷体加粗文字在《北京阳光诺和药物研究股份有限公司发行股份及可转换公司 债券购买资产并募集配套资金暨关联交易报告书（草案）（修订稿）》（以下简 称"《重组报告书（修订稿）》"）中显示。如无特殊说明，本回复中出现的简 称均与《重组报告书（修订稿）》中的释义内容相同，本文涉及数字均按照四舍 五入保留两位小数，合计数与各加数直接相加之和在尾数上可能略有差异，上述 差异是由于计算过程中四舍五入造成的。 证券代码：688621 证券简称：阳光诺和 公告 ...

股票代码：688621 股票简称：阳光诺和 上市地点：上海证券交易所 | | （修订稿） | | --- | --- | | 项目 | 交易对方 | | | 利虔、赣州朗颐投资中心（有限合伙）、刘宇晶、赣州国智股权投资合伙 | | | 企业（有限合伙）、杭州宏腾医药创业投资合伙企业（有限合伙）、杭州 | | | 方汭创业投资合伙企业（有限合伙）、杭州凯泰民德投资合伙企业（有限 | | | 合伙）、丽水同达创业投资合伙企业（有限合伙）、广州广发信德一期健 | | | 康产业投资企业（有限合伙）、杭州海达明德创业投资合伙企业（有限合 | | | 伙）、宁波海达睿盈创业投资合伙企业（有限合伙）、陈春能、广州易简 | | | 鼎虹股权投资合伙企业（有限合伙）、万海涛、苏州中誉赢嘉健康投资合 | | 发行股份 | 伙企业（有限合伙）、广州正达创业投资合伙企业（有限合伙）、康彦 | | 及可转换 | 龙、冯海霞、武汉火炬创业投资有限公司、武汉开发投资有限公司、珠海 | | 公司债券 | 横琴中润康健投资合伙企业（有限合伙）、嘉兴迦得股权投资合伙企业 | | 购买资产 | （有限合伙）、广发乾和投资有限公司、杭州凯泰睿德创 ...

Core Viewpoint - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, while also raising matching funds from no more than 35 specific investors [1] Group 1 - The controlling shareholder, Li Qian, and his concerted parties currently hold 28.27% of the company's shares, which will increase to over 30% post-transaction [1] - The company's board has proposed to the shareholders' meeting to approve Li Qian and his concerted parties' request to be exempt from making a tender offer for additional shares, pending approval from the shareholders' meeting [1]

北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料 二〇二五年十一月 1 / 38 北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料 北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料目录 | 2025 年第四次临时股东会会议须知 3 | | --- | | 2025 年第四次临时股东会会议议程 6 | | 议案二：关于公司发行股份及可转换公司债券购买资产并募集配套资金暨关联交易方 | | 案（调整后）的议案 10 | | 议案三：关于《阳光诺和发行股份及可转换公司债券购买资产并募集资金暨关联交易 | | 报告书（草案）（修订稿）》及其摘要的议案 35 | | 议案二十六：关于签署附条件生效的《发行股份及可转换公司债券购买资产之业绩补 | | 偿协议之补充协议》的议案 36 | | 议案二十七：关于提请股东会批准利虔及其一致行动人免于以要约方式增持公司股份 | | 的议案 37 | 重要提示：除上述议案外，其余会议资料 ...

Core Insights - The medical services sector experienced a rise of 1.67% on October 31, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 34.46, up 11.20% with a trading volume of 158,200 shares and a transaction value of 530 million [1] - Other notable performers included: - Nanmo Biological (688265) at 50.60, up 9.98% [1] - Nuo Si Ge (301333) at 68.59, up 7.00% [1] - Yangguang Nuohe (688621) at 58.75, up 5.10% [1] - *ST Biological (000504) at 9.57, up 5.05% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 461 million from institutional investors, while retail investors experienced a net inflow of 918,230 [2] - Notable capital flows included: - Innovation Medical (002173) with a net inflow of 14.416 million from institutional investors [3] - Tai Ge Medical (300347) with a net inflow of 70.6534 million from institutional investors [3] - Zhaoyan New Drug (603127) with a net inflow of 53.6731 million from institutional investors [3]

Core Insights - The 2025 High-Quality Development Forum and the 27th Golden Bull Award Ceremony were held in Nantong, Jiangsu, with the theme "Moving Towards New Heights, Achieving Practical Results, and Enlightening the Future" [1] - Sunshine Nuohuo won the "New Quality Enterprise Golden Bull Award" due to its strong development momentum and stable operating performance [1][5] Group 1: Award Overview - The Golden Bull Award, established in 1999 by China Securities Journal, aims to create a credible and authoritative platform for showcasing listed companies in the capital market [4] - The award recognizes companies with standardized governance, performance growth, and positive shareholder and societal returns [4] Group 2: Award Categories and Winners - This year's Golden Bull Award featured nine categories, including "Most Investment Value Award" and "New Quality Enterprise Golden Bull Award," with 55 companies receiving the latter [5] - Sunshine Nuohuo is a professional CRO providing comprehensive drug development services for domestic pharmaceutical companies and research institutions [5] Group 3: Company Performance - For the first three quarters of 2025, Sunshine Nuohuo reported revenue of 856 million yuan and a net profit attributable to shareholders of 163 million yuan [5] - The net cash flow from operating activities reached 148 million yuan, reflecting a year-on-year increase of 36.63% [5]

Group 1 - The core point of the article highlights the performance of Yangguang Nuohuo, which saw a stock price increase of 5.04% to 58.72 CNY per share, with a trading volume of 174 million CNY and a turnover rate of 2.70%, resulting in a total market capitalization of 6.577 billion CNY [1] - Yangguang Nuohuo is a comprehensive research and development service company established on March 9, 2009, and listed on June 21, 2021, primarily engaged in the development of generic drugs, consistency evaluation, and innovative drug development, with 99.91% of its revenue coming from CRO services [1] Group 2 - From the perspective of major shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B fund reduced its holdings by 550,000 shares in the third quarter, now holding 2 million shares, which represents 1.79% of the circulating shares, with an estimated floating profit of approximately 5.64 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund, managed by Wan Minyuan, has a total asset size of 5.957 billion CNY, with a best return of 144.04% and a worst return of -20.09% during his tenure [3] Group 3 - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has Yangguang Nuohuo as its sixth-largest holding, accounting for 5.44% of the fund's net value, with a floating profit of approximately 5.64 million CNY [4]

Core Viewpoint - 阳光诺和 is a leading drug research outsourcing service provider in China, specializing in generic and innovative drug development services, with strong technical capabilities and extensive project experience [1] Group 1: Business Overview - 阳光诺和 was established on March 9, 2009, and listed on the Shanghai Stock Exchange on June 21, 2021, with its registered and office address in Beijing [1] - The main business includes generic drug development, consistency evaluation, and innovative drug development, covering pharmaceutical research, clinical trials, and bioanalysis [1] Group 2: Financial Performance - For Q3 2025, 阳光诺和 reported revenue of 856 million yuan, ranking 11th among 29 companies in the industry, while the industry leader, 药明康德, achieved revenue of 32.857 billion yuan [2] - The net profit for the same period was 164 million yuan, placing the company 7th in the industry, with 药明康德 leading at 12.206 billion yuan [2] - The company's CRO business generated 590 million yuan, accounting for 99.91% of total revenue, while other business segments contributed 549,700 yuan [2] Group 3: Financial Ratios - As of Q3 2025, 阳光诺和's debt-to-asset ratio was 47.30%, higher than the previous year's 45.65% and the industry average of 22.79% [3] - The gross profit margin for Q3 2025 was 50.75%, down from 52.15% year-on-year but still above the industry average of 37.70% [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 6.76% to 9,204, while the average number of circulating A-shares held per account decreased by 6.33% to 12,200 [5] - The sixth largest circulating shareholder is 融通健康产业灵活配置混合A/B, holding 2 million shares, down by 550,000 shares from the previous period [5] Group 5: Strategic Developments - 华鑫证券 noted that 阳光诺和 plans to acquire 朗研生命 to enhance its industrial layout, aiming for a "CRO + pharmaceutical industry" strategy [6] - The company’s self-developed innovative drug STC007 injection is entering a critical clinical stage, with expectations for at least one product to enter clinical trials by 2026 [6] - Revenue forecasts for 阳光诺和 from 2025 to 2027 are projected at 1.259 billion, 1.415 billion, and 1.615 billion yuan, respectively, with corresponding EPS of 2.06, 2.41, and 2.96 yuan [6]

Core Viewpoint - 阳光诺和's revenue and net profit have declined in the first three quarters of 2025, primarily due to the impact of policy changes on its generic drug business [1] Financial Performance - The company reported a revenue of 856 million yuan, representing a year-on-year decrease of 6.65% [1] - The net profit attributable to the company was 163 million yuan, down 21.38% year-on-year [1] Business Impact - The decline in revenue is attributed to the effects of centralized procurement and the MAH (Marketing Authorization Holder) system [1] - Increased cost rates and new equity incentive expenses during the reporting period contributed to the decrease in net profit [1]